Literature DB >> 19321466

Encephalopathic attacks in a family co-segregating myotonic dystrophy type 1, an intermediate Charcot-Marie-Tooth neuropathy and early hearing loss.

F Spaans1, C G Faber, H J M Smeets, P A M Hofman, C Braida, D G Monckton, C E M de Die-Smulders.   

Abstract

OBJECTIVE: To report new disease components in a unique myotonic dystrophy type 1 (DM1) family previously described by us in which all affected members also had a sensorimotor neuropathy that co-segregated with markers flanking the DM1 locus.
METHODS: Clinical observations, electrophysiology, audiometry, DNA studies.
RESULTS: During a follow-up period of over 25 years, the following were observed: (i) co-segregation of a striking new encephalopathic phenotype. In middle age, five patients were admitted on multiple occasions with attacks of impaired consciousness, psychomotor agitation, fever and, in about half of the cases, focal neurological signs, including unilateral weakness, sensory deficits and dysphasia. Reported onset phenomena consisted of confusion, headache, focal neurological symptoms and nausea; (ii) many patients show an early and severe sensorineural hearing loss; (iii) although they have mothers with the adult onset type, the four affected subjects from the youngest generation do not show any signs or symptoms of childhood or congenital myotonic dystrophy; (iv) the neuropathy meets the criteria of an intermediate type Charcot-Marie-Tooth (CMT), and is more severe in males; and (v) patients presented with an expanded fragment at the DM1 CTG repeat but this allele was refractory to PCR amplification and triplet repeat primed PCR at the 3' end of the array, indicating the existence of an additional lesion at the 3' end.
CONCLUSIONS: The phenotype in this unique family extends beyond myotonic dystrophy and CMT to include encephalopathic attacks and early hearing loss, and is associated with an atypical mutation at the DM1 locus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321466     DOI: 10.1136/jnnp.2008.170126

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

1.  Myotonic dystrophy type I combined with X-linked dominant Charcot-Marie-Tooth neuropathy.

Authors:  Hyun Sook Kim; Ki Wha Chung; Sung Hee Kang; Sung Kyung Choi; Sun Young Cho; Heasoo Koo; Sang-Beom Kim; Byung-Ok Choi
Journal:  Neurogenetics       Date:  2010-05-05       Impact factor: 2.660

2.  A complex phenotype of peripheral neuropathy, myopathy, hoarseness, and hearing loss is linked to an autosomal dominant mutation in MYH14.

Authors:  Byung-Ok Choi; Sung Hee Kang; Young Se Hyun; Sumaria Kanwal; Sun Wha Park; Heasoo Koo; Sang-Beom Kim; Young-Chul Choi; Jeong Hyun Yoo; Jong-Won Kim; Kee Duk Park; Kyoung-Gyu Choi; Song Ja Kim; Stephan Züchner; Ki Wha Chung
Journal:  Hum Mutat       Date:  2011-04-07       Impact factor: 4.878

Review 3.  Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Authors:  José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

4.  Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures.

Authors:  Karen N McFarland; Jilin Liu; Ivette Landrian; Desmond Zeng; Salmo Raskin; Mariana Moscovich; Emilia M Gatto; Adriana Ochoa; Hélio A G Teive; Astrid Rasmussen; Tetsuo Ashizawa
Journal:  Neurogenetics       Date:  2013-12-07       Impact factor: 2.660

5.  Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.

Authors:  A Matilla-Dueñas; T Ashizawa; A Brice; S Magri; K N McFarland; M Pandolfo; S M Pulst; O Riess; D C Rubinsztein; J Schmidt; T Schmidt; D R Scoles; G Stevanin; F Taroni; B R Underwood; I Sánchez
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.